The facts
AP and CHAI report that the FDA granted Dr. Reddy’s Laboratories tentative approval for the first generic injectable lenacapavir used for HIV prevention. The action is tentative; it is not permission to market the generic in the United States while the branded drug remains under patent. [1][2]
CHAI says the existing licensing arrangement targets US$40 per person per year in 120 low- and middle-income countries covered by Gilead’s voluntary license. [2]
CHAI expects initial supplies by the end of 2026 and wider availability in 2027; STAT separately reports the company expected shipping to begin next month. These are forecasts, not evidence of current supply. [2][3]
Still unconfirmed
- The FDA letter’s complete terms and the date any U.S. patent/exclusivity barrier ends were not established in the reviewed reports.
- Country-by-country authorization, procurement, funding, launch dates and actual patient access remain unknown.
- No purchase commitments or uptake totals were reported.
Sources
References support the numbered facts above. Source checks: 2 Nov 2026, 22:32 UTC.
The FDA’s approval letter was not located in the checked drug database and press-announcement pages. AP and CHAI independently report the tentative approval; CHAI is a development partner and primary source for access and pricing targets. Rollout remains prospective.
- Approval of a cheap version of HIV-prevention shot lenacapavir raises hopes in low-income countries
The Associated Press · Reporting · 2 Nov 2026
Opened AP’s report published 2 November. It explains the FDA designation as tentative, says the generic cannot yet be marketed in the United States because of patent protection, and reports the access and pricing plan.
- U.S. FDA approves first generic injectable lenacapavir for HIV prevention
Clinton Health Access Initiative · Primary source · 2 Nov 2026
Opened CHAI’s 2 November partner announcement. The body specifically says FDA tentative approval, a US$40-per-person-year target across 120 licensed low- and middle-income countries, initial supplies by end-2026 and wider availability in 2027.
- Generic lenacapavir for HIV prevention gets FDA tentative approval
STAT · Reporting · 2 Nov 2026
Opened STAT’s independent report. It attributes the company’s expected shipping start to next month; that timetable is a forecast, not current availability.